Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OPA1 is a mitochondrial inner membrane GTPase essential for mitochondrial inner membrane fusion, maintenance of cristae structure, and the integrity of mitochondrial DNA. It exists in multiple splice isoforms, localizes to the inner mitochondrial membrane, and is required for normal mitochondrial dynamics and energy production. Dysfunction or mutation of OPA1 leads to mitochondrial disorganization and increased susceptibility to apoptosis, contributing to dominantly inherited optic neuropathy (DOA), various neurological syndromes, and other mitochondrial diseases. Therapeutic targeting of OPA1 mRNA with antisense oligonucleotides is under investigation as a strategy to increase functional OPA1 protein in disorders such as dominant optic atrophy[1][2][3][4][5][6][8].
Splice-switching antisense oligonucleotides decrease inclusion of poison exons in OPA1 mRNA, increasing production of functional OPA1 protein
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynamin-like GTPase OPA1, mitochondrial (OPA1).